Prognostic and survival impact of BCL9 and RPS6KB1 copy number variation detected from circulating free DNA in hepatocellular carcinoma

References

• Feng J, Li J, Wu L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39(1):1–19.
   PubMed Web of Science ®Google Scholar
• Rashed WM, Kandeil MAM, Mahmoud MO, et al. Hepatocellular Carcinoma (HCC) in Egypt: a comprehensive overview. J Egypt Natl Canc Inst. 2020;32(1):1–11.
   PubMed Web of Science ®Google Scholar
• Research EOF, Cancer TO, Liver EAFTSOT. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng Y, Wu L, et al. Current status of ctDNA in precision oncology for hepatocellular carcinoma. J Exp Clin Cancer Res. 2021;40(1):1–17.
   PubMed Web of Science ®Google Scholar
• Li J, Han X, Yu X, et al. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. J Exp Clin Cancer Res. 2018;37(1):1–13.
   PubMedGoogle Scholar
• von Felden J, Craig AJ, Villanueva A. Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma. Oncoscience. 2018;5(7–8):209.
   PubMedGoogle Scholar
• Wu X, Li J, Gassa A, et al. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. Int J Biol Sci. 2020;16(9):1551.
   PubMed Web of Science ®Google Scholar
• Lu C-Y, Chen S-Y, Peng H-L, et al. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma. Oncotarget. 2017;8(4):6406.
   PubMedGoogle Scholar
• Ikeda S, Tsigelny IF, Skjevik ÅA, et al. Next‐generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma. Oncologist. 2018;23(5):586–593.
   PubMed Web of Science ®Google Scholar
• Jiao J, Niu W, Wang Y, et al. Prevalence of aflatoxin-associated TP53R249S mutation in hepatocellular carcinoma in Hispanics in South Texas. Cancer Prev Res. 2018;11(2):103–112.
   PubMed Web of Science ®Google Scholar
• Shibata T, Aburatani H. Exploration of liver cancer genomes. Nat Clin Pract Gastroenterol Hepatol. 2014;11(6):340–349.
   Google Scholar
• Molparia B, Oliveira G, Wagner JL, et al. A feasibility study of colorectal cancer diagnosis via circulating tumor DNA derived CNV detection. PloS one. 2018;13(5):e0196826.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang X, Zhou K, et al. Multiple-level copy number variations in circulating cell-free DNA for prognostic prediction of hepatocellular carcinoma with radical treatments. 2020
   Google Scholar
• Katoh H, Ojima H, Kokubu A, et al. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology. 2007;133(5):1475–1486.
   PubMed Web of Science ®Google Scholar
• Wang K, Lim HY, Shi S, et al. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology. 2013;58(2):706–717.
   PubMed Web of Science ®Google Scholar
• Roessler S, Long EL, Budhu A, et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology. 2012;142(4):957–966. e912.
   PubMed Web of Science ®Google Scholar
• Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012;44(6):694–698.
   PubMed Web of Science ®Google Scholar
• Stover DG, Parsons HA, Ha G, et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol. 2018;36(6):543.
   PubMed Web of Science ®Google Scholar
• Adalsteinsson VA, Ha G, Freeman SS, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8(1):1–13.
   PubMedGoogle Scholar
• Ding X, Tsang S-Y, Ng S-K, et al. Application of machine learning to development of copy number variation-based prediction of cancer risk. Genomics Insights. 2014;7(GEI):S15002.
   Google Scholar
• Furge KA, Dykema KJ, Ho C, et al. Comparison of array-based comparative genomic hybridization with gene expression-based regional expression biases to identify genetic abnormalities in hepatocellular carcinoma. BMC Genomics. 2005;6(1):1–10.
   PubMedGoogle Scholar
• Wang G, Zhao Y, Liu X, et al. Allelic loss and gain, but not genomic instability, as the major somatic mutation in primary hepatocellular carcinoma. Genes Chromosomes Cancer. 2001;31(3):221–227.
   PubMed Web of Science ®Google Scholar
• Huge N, Sandbothe M, Schröder AK, et al. Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma. Hepatol Int. 2020;14(3):373–384.
   PubMed Web of Science ®Google Scholar
• Xie X, Guo P, Yu H, et al. Ribosomal proteins: insight into molecular roles and functions in hepatocellular carcinoma. Oncogene. 2018;37(3):277–285.
   PubMed Web of Science ®Google Scholar
• Abbas EAER, Barakat AB, Hassany M, et al. The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients. J Genet Eng Biotechnol. 2022;20(1):1–9.
   PubMed Web of Science ®Google Scholar
• Huang A, Zhang X, Zhou S-L, et al. Plasma circulating cell-free DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma. J Cancer. 2016;7(13):1798.
   PubMed Web of Science ®Google Scholar
• Kunadirek P, Chuaypen N, Jenjaroenpun P, et al. Cell-free DNA analysis by whole-exome sequencing for hepatocellular carcinoma: a pilot study in Thailand. Cancers (Basel). 2021;13(9):2229.
   PubMed Web of Science ®Google Scholar
• Mandel P, Metais P. Nuclear acids in human blood plasma. Comptes rendus des seances de la Societe de biologie et de ses filiales. 1948;142(3–4):241–243.
   PubMedGoogle Scholar
• Shousha HI, Abdelaziz AO, Nabeel MM, et al. Schistosoma mansoni infection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade. Pathog Glob Health. 2022;116(2):119–127.
   PubMed Web of Science ®Google Scholar
• Oh CR, Kong S-Y, Im H-S, et al. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. BMC Cancer. 2019;19(1):1–13.
   PubMedGoogle Scholar